Nobuyuki Arima

Dr. Nobuyuki Arima

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2015 in Journal of Clinical Pathology
Verified
Journal Article
Open access
PDF file
NANobuyuki Arima
Nobuyuki Arima
RNReiki Nishimura
Reiki Nishimura
TOTomofumi Osako
Tomofumi Osako
YNYasuyuki Nishiyama
Yasuyuki Nishiyama
MFMamiko Fujisue
Mamiko Fujisue
YTYasuo Toyozumi
Yasuo Toyozumi
Aim Insufficient attention for the Ki-67 immunohistochemistry has been given to the importance of tissue handling for surgical breast cancer specimens. We sought to investigate the effect of fixation status on the Ki-67. Methods We examined the effect of fixative, time to and duration of fixation using surgical specimens, and finally, compared the paired Ki-67 index in the tumour between core needle and surgical specimen. Results The Ki-67 was significantly higher when 10% neutral buffered formalin was used (p=0.0276). Insufficient fixation caused a drastic reduction in the Ki-67 index (p=0.0177), but not significant in oestrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2). Sixteen hours delayed time to fixation also caused a reduction of the Ki-67 (p=0.0284), but not significant in ER. Prolonged fixation significantly led to a gradual reduction in the Ki-67 in a time-dependent manner, but not in both ER and HER2. Finally, cutting the tumour before fixation improved fixation status and consequently caused an increased level of the Ki-67 index (p=0.0181), which resulted in a strong correlation of the Ki-67 between core needle and surgical specimen (r=0.8595). Conclusions Tissue handling of surgical specimen is critical for assessing the Ki-67 compared with ER and HER2. We should pay more attention to tissue fixation status for the standard assessment of the Ki-67 index.

22 April 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
RNReiki Nishimura
Reiki Nishimura
TOTomofumi Osako
Tomofumi Osako
YOYasuhiro Okumura
Yasuhiro Okumura
MNMasahiro Nakano
Masahiro Nakano
HOHiroko Otsuka
Hiroko Otsuka
NANobuyuki Arima
Nobuyuki Arima
Background: Triple negative breast cancer (TNBC) is a subtype of breast cancer which lacks hormone receptor (HR) expression and HER2 gene amplification and is the most aggressive subtype, with a heterogeneous genetic profile. The aim of this retrospective study was to evaluate the clinical significance of menopausal status in breast cancer cases with TNBC. Methods: Primary breast cancer patients who underwent curative surgery were enrolled in this retrospective study. A total of 5153 invasive breast cancer cases with Stage I–III were analyzed. The distribution of cases according to the menopausal status and subtypes was investigated and the clinicopathological characteristics and prognosis were compared between pre- and postmenopausal TNBC patients. Results: TNBC was frequently seen in postmenopausal patients and Luminal B and Luminal/HER2 subtypes were more common in premenopausal patients. There was no difference in DFS in the Luminal A/B and HER2 subtypes, but a significant difference was seen in the TNBC patients. Premenopausal patients with TNBC frequently had an overexpression of the p53 protein, a significantly higher Ki-67 index value, and a higher nuclear grade. A multivariate analysis revealed that menopausal status, nodal status, and tumor size were significant factors for DFS in TNBC cases. Conclusion: Menopausal status significantly correlates with breast cancer subtypes. TNBC was often seen in postmenopausal patients and these patients tend to have more favorable factors and a better DFS than premenopausal patients. These findings suggest that menopausal status is an important factor for evaluating biology and prognosis in TNBC cases.

7 September 2023 in Cancers
Verified
Journal Article
Open access
PDF file
KMKimihisa Mizoguchi
Kimihisa Mizoguchi
HKHitomi Kawaji
Hitomi Kawaji
MKMasaya Kai
Masaya Kai
TMTakafumi Morisaki Morisaki
Takafumi Morisaki Morisaki
SHSaori Hayashi
Saori Hayashi
MKMakoto Kubo
Makoto Kubo
Tumor-infiltrating lymphocytes in the tumor microenvironment are important in the treatment of triple-negative breast cancer (TNBC). Cytotoxic T cells produce cytokines and cytotoxic factors, such as perforin and granzyme, which induce apoptosis by damaging target cells. To identify biomarkers of these cells, we investigated granzyme B (GZMB) in the tumor microenvironment as a biomarker of treatment response and prognosis in 230 patients with primary TNBC who underwent surgery without preoperative chemotherapy between January 2004 and December 2014. Programmed cell death ligand 1 (PD-L1) positivity was defined as a composite positive score ≥10 based on the PD-L1 immunostaining of tumor cells and immune cells. GZMB-high was defined as positivity in ≥1% of tumor-infiltrating lymphocytes (TILs). Among the 230 TNBC patients, 117 (50.9%) had CD8-positive infiltrating tumors. In the PD-L1-positive group, a Kaplan–Meier analysis showed that GZMB-high TNBC patients had better recurrence-free survival (RFS) and overall survival (OS) than GZMB-low patients and that OS was significantly longer (RFS: p = 0.0220, OS: p = 0.0254). A multivariate analysis also showed significantly better OS in PD-L1- and GZMB-high patients (hazard ratio: 0.25 (95% IC: 0.07–0.88), p = 0.03). Our findings indicate that GZMB is a useful prognostic biomarker in PD-L1-positive TNBC patients.

29 October 2018 in Oncology Letters
Verified
Journal Article
Closed access
PDF file
NANobuyuki Arima
Nobuyuki Arima
RNReiki Nishimura
Reiki Nishimura
TOTomofumi Osako
Tomofumi Osako
YOYasuhiro Okumura
Yasuhiro Okumura
MNMasahiro Nakano
Masahiro Nakano
YTYasuo Toyozumi
Yasuo Toyozumi
Gene profiling has identified at least 4 breast cancer subtypes, including Luminal A, Luminal B, HER2‑enriched and basal‑like, and immunohistochemistry is used as a guide to determine these subtypes. In the present study, patients with ER‑positive, HER2‑negative and negative nodes were classified into 4 groups according to the PgR and the Ki‑67 status and were retrospectively examined. The analysis was based on the clinicopathological findings, and includes the recurrence score (RS) and disease‑free survival (DFS) rates. Patients with invasive breast cancer (n=1866) were classified as LA (high PgR/low Ki‑67), LB‑1 (high PgR/high Ki‑67), LB‑2 (low PgR/high Ki‑67), and LB‑3 (low PgR/low Ki‑67). In addition, 41 of the cases underwent a 21‑gene expression assay. The data revealed that T1 tumors were more prevalent in the LA group and rare in the LB‑2 group. Furthermore, nuclear grade 3 and p53 overexpression was revealed to be significantly correlated with LB‑2. In terms of prognosis, LA had a significantly more favorable DFS; however, no differences were observed in the LB‑3 group. LB‑2 had a significantly worse DFS in all cases, and in the cases administered with endocrine therapy alone. Chemotherapy in combination with endocrine therapy was administered to cases with a higher risk of recurrence. In the LB‑2 group, there was no difference in the DFS rates between the cases with endocrine therapy and chemo‑endocrine therapy. These findings suggest that chemotherapy could improve the DFS in the LB‑2 group. In addition, the majority of cases with LA, LB‑3 and LB‑1 had a RS of ≤25 and the majority of the LB‑2 cases had a RS of >25. The patients with LA and LB‑3 had a favorable DFS even in the group that received endocrine therapy alone. LB‑2 was significantly correlated with a higher degree of malignancy and benefited from chemotherapy. These data suggest that the PgR and the Ki‑67 status are effective in predicting prognosis, and for deciding on the most effective treatment strategy in patients with breast cancer.

6 January 2013 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
MIMakoto Ishitobi
Makoto Ishitobi
YOYasuhiro Okumura
Yasuhiro Okumura
NANobuyuki Arima
Nobuyuki Arima
AYAtsushi Yoshida
Atsushi Yoshida
KNKatsuhiko Nakatsukasa
Katsuhiko Nakatsukasa
HIHideo Inaji
Hideo Inaji

28 November 2015 in Oncology
Verified
Journal Article
Closed access
PDF file
NANobuyuki Arima
Nobuyuki Arima
RNReiki Nishimura
Reiki Nishimura
TOTomofumi Osako
Tomofumi Osako
YNYasuyuki Nishiyama
Yasuyuki Nishiyama
MFMamiko Fujisue
Mamiko Fujisue
YTYasuo Toyozumi
Yasuo Toyozumi
Objective: In this case-control study, we investigated the most suitable cell counting area and the optimal cutoff point of the Ki-67 index. Methods: Thirty recurrent cases were selected among hormone receptor (HR)-positive/HER2-negative breast cancer patients. As controls, 90 nonrecurrent cases were randomly selected by allotting 3 controls to each recurrent case based on the following criteria: age, nodal status, tumor size, and adjuvant endocrine therapy alone. Both the hot spot and the average area of the tumor were evaluated on a Ki-67 immunostaining slide. Results: The median Ki-67 index value at the hot spot and average area were 25.0 and 14.5%, respectively. Irrespective of the area counted, the Ki-67 index value was significantly higher in all of the recurrent cases (p < 0.0001). The multivariate analysis revealed that the Ki-67 index value of 20% at the hot spot was the most suitable cutoff point for predicting recurrence. Moreover, higher ΔKi-67 index value (the difference between the hot spot and the average area, ≥10%) and lower progesterone receptor expression (<20%) were significantly correlated with recurrence. Conclusion: A higher Ki-67 index value at the hot spot strongly correlated with recurrence, and the optimal cutoff point was found to be 20%.